

# UNITED STATES PARTMENT OF COMMERCE United States Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

	APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR		ATTORNEY DOCKET NO.
	09/781,301	02/13/01	DI PIERRO	F	7914-073
Г	020582		HM22/0612	·	EXAMINER
	PENNIE & E		(II) Marie / COLE	FLOC	
•	SUITE 1000 WASHINGTON			<u> </u>	PAPER NUMBER
	MHOUTINGLOIM	re zooce		1651 DATE MAILED	
					06/12/01

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner of Patents and Trademarks** 

## Office Action Summary

Application No. 09/781,301

Applicant(s)

Examiner

Michele Flood

Art Unit 1651

**Applicant** 

	и
	11
- 1 LE B   B   3   B   4   B   B   1   B   B   1   E   B   1   F   B   1   F	I
	I
- 3 (80)83 ((8) 00(8) 38)9( 38(8) (8)	H
- 1 (# 8/8) 3/8	ı

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE \_\_\_\_\_\_ MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status 1) Responsive to communication(s) filed on Feb 13, 2001 2a) This action is **FINAL**. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213. Disposition of Claims 4) X Claim(s) 1-17 is/are pending in the application. 4a) Of the above, claim(s) \_\_\_\_\_\_ is/are withdrawn from consideratio 5) Claim(s) \_\_\_\_\_ 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) 💢 Claims 1-17 are subject to restriction and/or election requirement **Application Papers** 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on \_\_\_\_\_\_ is/are objected to by the Examiner. 11) The proposed drawing correction filed on \_\_\_\_\_\_ is: a) approved b) disapproved. 12) The oath or declaration is objected to by the Examiner. Priority under 35 U.S.C. § 119 13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d). a) ☐ All b) ☐ Some\* c) ☐ None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. 
Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). \*See the attached detailed Office action for a list of the certified copies not received. 14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e). Attachment(s) 15) Notice of References Cited (PTO-892) 18) Interview Summary (PTO-413) Paper No(s). 16) Notice of Draftsperson's Patent Drawing Review (PTO-948) 19) Notice of Informal Patent Application (PTO-152) 17) Information Disclosure Statement(s) (PTO-1449) Paper No(s). 20) Other:

Art Unit: 1651

## Page 2

### **DETAILED ACTION**

#### Election/Restriction

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - I. Claims 1-15, drawn to a cosmetic composition comprising an active ingredient comprising a fatty acid or an antiandrogenic sterol from *Serenoa* or from *Cucurbita* seeds in a therapeutically effective amount sufficient to provide a retarding action of the growth of superfluous hair, classified in class 424, subclass 724 or class 424, subclass 758, or class 424, subclass 752, or class 424, subclass 732, or class 424, subclass 725, or class 514, subclass 25, or class 536, subclass 8 or class 536, subclass 4.4, or class 536, subclass 6.1, or class 536, subclass 4.1, for example.
  - II. Claims 16-17, drawn to a cosmetic treatment method, which comprises applying to a region of the body having superfluous hair a composition comprising an active ingredient comprising a fatty acid or an antiandrogenic sterol from *Serenoa* or from *Cucurbita* seeds in a therapeutically effective amount sufficient to provide a retarding action of the growth of superfluous hair, classified in class 424, subclass 70.1 or class 8, subclass 94.17, for example.
- 2. The inventions are distinct, each from the other because of the following reasons:

  Inventions I and II are related as product and process of use. The inventions can be shown to be

Art Unit: 1651

Page 3

distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the process for retarding action on the growth of superfluous hair can be practiced with two different materially different products, as shown by the claims themselves.

- 3. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.
- 4. Because these inventions are distinct for the reasons given above and the search required for one Group is not required for another Group, restriction for examination purposes as indicated is proper.
- 5. This application contains claims directed to the following patentably distinct species of the claimed invention: the distinct ingredients of Claims 1 and 16, wherein the active ingredient comprising a fatty acid or antiandrogenic sterol is from *Serenoa* or from *Cucurbita* seeds; and, the distinct ingredients of Claim 3, wherein the anti-inflammatory or vasal protective agents are triterpenes from liquorice, saponins from a horse chestnut plant, triterpenes from *Terminalia* sericea, isobutylamides from *Zanthoxylum bungeanum*, gingkoflavonegluccosides and terpenes from *Gingko*, polyphenols from grape seeds, anthocyanosides from bilberries, saponins from butcher's broom, or a mixture thereof.

Art Unit: 1651

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, Claims 2, 4, 7-15 and 17 are generic.

Page 4

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

A telephone call was made to Victor Balancia on June 11, 2001 to request an oral election 6. to the above restriction requirement, but did not result in an election being made.

Art Unit: 1651

Applicant is advised that the reply to this requirement to be complete must include an

election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

7. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the

inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently

named inventors is no longer an inventor of at least one claim remaining in the application. Any

amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the

fee required under 37 CFR 1.17(I).

8. Any inquiry concerning this communication or earlier communications from the examiner

should be directed to Michele Flood whose telephone number is (703) 308-9432.

CHRISTOPHER R. TATE
PRIMARY EXAMINER

Page 5

**MCF** 

June 11, 2001